Loading
A phase 2 trial in triple-negative breast cancer, run by JenKem Technology Co., Ltd., not yet recruiting.
JK-1201I in Triple Negative Breast Cancer Patients with Brain Metastases is a phase 2, interventional study registered as NCT06586866 by JenKem Technology Co., Ltd., with a registry enrolment figure of 25 participants, started 2024-09-26 and due to reach its primary completion in 2026-05-26. Interventions recorded: JK-1201I. Conditions listed: Triple Negative Breast Cancer (TNBC); Brain Metastasases. Triple-negative eligibility wording from the registry: "Histological or cytological confirmation of triple-negative breast cancer (TNBC)". No results are recorded here; the registry entry is the source.
Shares Brain metastases (intracranial disease), Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites) and the tag tnbc-deep-dive.
Shares Brain metastases (intracranial disease), Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites) and the tag tnbc-deep-dive.
Shares Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites) and the tag tnbc-deep-dive.
Shares Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites) and the tag tnbc-deep-dive.
Shares Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites) and the tag tnbc-deep-dive.
Shares Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites) and the tag tnbc-deep-dive.
Shares Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites) and the tag tnbc-deep-dive.
Shares Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites) and the tag tnbc-deep-dive.